Cell therapy weekly: FDA issues statement marking halfway point in enforcement period for unproven regenerative medicine therapies
This week: Editas and BlueRock combine proprietary technology to develop engineered cell therapies and tissue-softening enzyme supports corneal regeneration.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>